Benzinga

Benzinga

Benzinga

martes, agosto 25

Revolution Medicines Inc

RVMDNASDAQ
Trade with Public
Trade with Public
$211.38
-0.20-0.09%
al cierre: Aug 25, 5:00 PM EST
$211.38
N/A
After hour: 7:13 PM EST
Panorámica generalNoticiasPrevisión de beneficiosEventosPrecios objetivoFinanzasSentimientoPropiedadCompararOpcionesInforme de acciones

Revolution Medicines Analyst Price Targets

Wall Street analyst price targets and consensus rating for Revolution Medicines (RVMD).

Price Target Range — 8 Quarters

Analyst Consensus — 21 Analysts

1S.Buy
19Buy
1Hold
Consensus RatingBuy# Analysts21Avg. Consensus PT$146Upside to Avg. PT-30.9%

Rating Trend — Last 9 Months

Recent Analyst Actions

View all ratings →
DateFirmAnalystActionRating ChangePrice Target
Aug 21, 2026BernsteinJeffrey WalchPT RaiseMarket Perform$151→$179
Aug 11, 2026Truist SecuritiesGregory RenzaPT RaiseBuy$210→$231
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Bernstein Maintains Market Perform on Revolution Medicines, Raises Price Target to $179

Bernstein analyst Jeffrey Walch maintains Revolution Medicines (NASDAQ:RVMD) with a Market Perform and raises the price target from $151 to $179.
Benzinga Newsdesk

PRO
Truist Securities Maintains Buy on Revolution Medicines, Raises Price Target to $231

Truist Securities analyst Gregory Renza maintains Revolution Medicines (NASDAQ:RVMD) with a Buy and raises the price target from $210 to $231.
Benzinga Newsdesk

PRO
RBC Capital Maintains Outperform on Revolution Medicines, Raises Price Target to $203

RBC Capital analyst Leonid Timashev maintains Revolution Medicines (NASDAQ:RVMD) with a Outperform and raises the price target from $182 to $203.
Benzinga Newsdesk

PRO
Wedbush Maintains Outperform on Revolution Medicines, Raises Price Target to $201

Wedbush analyst Robert Driscoll maintains Revolution Medicines (NASDAQ:RVMD) with a Outperform and raises the price target from $192.1 to $201.
Benzinga Newsdesk

PRO
Evercore ISI Group Maintains Outperform on Revolution Medicines, Raises Price Target to $230

Evercore ISI Group analyst Cory Kasimov maintains Revolution Medicines (NASDAQ:RVMD) with a Outperform and raises the price target from $220 to $230.
Benzinga Newsdesk

PRO
Guggenheim Maintains Buy on Revolution Medicines, Raises Price Target to $240

Guggenheim analyst Michael Schmidt maintains Revolution Medicines (NASDAQ:RVMD) with a Buy and raises the price target from $235 to $240.
Benzinga Newsdesk

Datos y APIs: APIs de Benzinga · API de noticias de acciones · API de calificaciones de analistas · API de logotipos de empresas

Datos de mercado proporcionados por APIs de Benzinga

Benzinga

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

© 2026 Benzinga | All Rights Reserved